Morgan Stanley Janux Therapeutics, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 121,231 shares of JANX stock, worth $5.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

121,231

Previous 67,448 79.74%

Holding current value

$5.08 Million

Previous $723,000 531.26%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.93 - $49.75 $426,499 - $2.68 Million	53,783 Added 79.74%	121,231 $4.56 Million
Q4 2023 Feb 13, 2024	BUY	$5.85 - $11.7 $274,903 - $549,806	46,992 Added 229.72%	67,448 $723,000
Q3 2023 Nov 15, 2023	BUY	$9.56 - $14.0 $18,881 - $27,650	1,975 Added 10.69%	20,456 $206,000
Q2 2023 Aug 14, 2023	SELL	$11.08 - $15.92 $166,454 - $239,166	-15,023 Reduced 44.84%	18,481 $219,000
Q1 2023 May 15, 2023	BUY	$11.25 - $22.21 $180,225 - $355,804	16,020 Added 91.63%	33,504 $405,000

Q4 2022 Feb 14, 2023	SELL	$11.1 - $18.26 $1.38 Million - $2.26 Million	-123,996 Reduced 87.64%	17,484 $230,000
Q3 2022 Nov 14, 2022	BUY	$10.82 - $16.84 $1.23 Million - $1.92 Million	113,747 Added 410.15%	141,480 $1.92 Million
Q2 2022 Oct 27, 2022	SELL	$9.52 - $15.65 $95 - $156	-10 Reduced 0.04%	27,733 $337,000
Q2 2022 Aug 15, 2022	SELL	$9.52 - $15.65 $95 - $156	-10 Reduced 0.04%	27,733 $337,000
Q1 2022 Oct 27, 2022	BUY	$13.24 - $20.24 $132 - $202	10 Added 0.04%	27,743 $398,000
Q1 2022 May 13, 2022	BUY	$13.24 - $20.24 $175,615 - $268,463	13,264 Added 91.61%	27,743 $398,000
Q4 2021 Feb 14, 2022	BUY	$15.44 - $27.32 $120,076 - $212,467	7,777 Added 116.04%	14,479 $285,000
Q3 2021 Nov 15, 2021	BUY	$20.7 - $34.69 $138,731 - $232,492	6,702 New	6,702 $145,000

Others Institutions Holding JANX

# of Institutions

123

Shares Held

25.3M

Call Options Held

92K

Put Options Held

161K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.75B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account